AnaptysBio, Inc. ANAB
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 232.39M | 234.60M | 169.47M | 123.16M | 111.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 232.39M | 234.60M | 169.47M | 123.16M | 111.87M |
| Cost of Revenue | 128.78M | 135.97M | 153.00M | 163.81M | 167.98M |
| Gross Profit | 103.61M | 98.63M | 16.47M | -40.64M | -56.11M |
| SG&A Expenses | 62.81M | 50.74M | 45.14M | 45.50M | 44.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 191.59M | 186.71M | 198.14M | 209.30M | 212.16M |
| Operating Income | 40.80M | 47.90M | -28.68M | -86.14M | -100.29M |
| Income Before Tax | -26.63M | -13.07M | -84.55M | -132.52M | -140.58M |
| Income Tax Expenses | 160.00K | 164.00K | 77.00K | 77.00K | 47.00K |
| Earnings from Continuing Operations | -26.79 | -13.23 | -84.63 | -132.59 | -140.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.79M | -13.23M | -84.63M | -132.59M | -140.62M |
| EBIT | 40.80M | 47.90M | -28.68M | -86.14M | -100.29M |
| EBITDA | 41.34M | 48.46M | -28.10M | -85.56M | -99.70M |
| EPS Basic | -0.86 | -0.30 | -2.80 | -4.48 | -4.84 |
| Normalized Basic EPS | -0.53 | -0.18 | -1.30 | -2.35 | -2.58 |
| EPS Diluted | -1.08 | -0.52 | -2.82 | -4.48 | -4.85 |
| Normalized Diluted EPS | -0.67 | -0.32 | -1.31 | -2.35 | -2.58 |
| Average Basic Shares Outstanding | 85.33M | 87.29M | 117.74M | 118.80M | 117.34M |
| Average Diluted Shares Outstanding | 115.54M | 117.49M | 118.92M | 118.80M | 117.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |